Dr Liu-Ying Luo is currently a staff scientist in R&D Systems, Inc. (Minneapolis, MN). Her main focus is to develop protease-related products for the research and diagnostic communities. Dr. Luo received her Bachelor of Medicine degree in China. She then moved to Canada and obtained her Ph.D in Laboratory Medicine and Pathobiology from the University of Toronto in 2002. Dr Luo’s research interests have been focused on discovery of novel cancer biomarkers, immunoassay development, and enzymology. As a graduate student, she cloned and characterized a serine protease gene, human tissue kallikrein 10. She developed the first immunoassay for this protein and measured its levels in biological fluids and tissue extracts. She discovered that human tissue kallikrein 10 offers great potential as a biomarker for ovarian and breast cancer. To elucidate the biological roles of kallikreins in various malignancies, she extended her research into functional characterization of the human tissue kallikreins. She described for the first time, the purification and functional characterization of human tissue kallikrein 11, a candidate prostate cancer biomarker, from seminal plasma. Dr. Luo has authored or co-authored 25 peer-reviewed papers and one chapter in the Handbook of Proteolytic Enzymes. She has reported 11 novel gene sequences in the Genbank database and is a co-inventor of three patents. Dr. Luo received the AACC Award for Outstanding Scientific Achievements by a Young Investigator in 2005 and the NACB George Grannis Award in 2002.